Latest Breaking News On - Phio pharmaceuticals corp - Page 12 : comparemela.com

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesAshleyr robinsonMichael adamsHc wainwright coPrnewswire phio pharmaceuticals corpContact phio pharmaceuticals corpPhio pharmaceuticals corpExchange commissionSecurities actPrivate securities litigation reform actAnnual reportSci advisors

Phio Pharmaceuticals (PHIO) Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals (PHIO) Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesPhio pharmaceuticals corpExchange commissionHc wainwright coWall street

Wade G W & Inc Decreases Holdings in iShares TIPS Bond ETF (NYSEARCA:TIP)

Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Rating) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 15,000 shares, a decline of 49.8% from the April 30th total of 29,900 shares. Approximately 1.0% of the shares of the company are sold short. Based on […]

United kingdomPhio pharmaceuticals corpCambridge investment research advisors incHedge funds weigh in on phio pharmaceuticalsVanguard group incPhio pharmaceuticals stock performancePhio pharmaceuticalsNews ratings for phio pharmaceuticals dailyPhio pharmaceuticals company profileRenaissance technologiesGet ratingInvestment research advisorsCetera investment advisersInvestment advisersPhio pharmaceuticals dailyNasdaq phio

Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx s Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute

/PRNewswire/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is.

United statesBridge viewRobert bittermanBrendan curtiRobertw franzAndrew weinbergMichael adamsAshleyr robinsonClinical researchJoseph healthEarlea chiles research instituteProvidence cancer instituteProvidence cancer institute in portlandPrnewswire phio pharmaceuticals corpPhio pharmaceuticals corpProvidence cancer institute of oregon

Phio Pharma Stock Jumps 14% As Cancer Drug Trial Set For Patient Enrollment

Shares of Phio Pharmaceuticals Corp. (PHIO) are gaining over 14% on Wednesday morning after the company announced its clinical development partner, AgonOx, Inc, in collaboration with Providence Cancer Institute, has completed the site initiation visit and can commence with patient accrual.

United statesRobertw franzBrendan curtiAndrew weinbergEarlea chiles research instituteAgonox incProvidence cancer institute in portlandPhio pharmaceuticals corpProvidence cancer instituteClinical researchPhio pharmaceuticalsPrincipal investigator brendan curtiMedical oncologistEndowed chairResearch instituteProvidence cancer